Characteristics of secondary progressive multiple sclerosis: Disease activity and provision of care in Germany - A registry-based/multicentric cohort study
- PMID: 34624644
- DOI: 10.1016/j.msard.2021.103281
Characteristics of secondary progressive multiple sclerosis: Disease activity and provision of care in Germany - A registry-based/multicentric cohort study
Abstract
Background: The tailored immunomodulatory treatment strategy for secondary progressive multiple sclerosis (SPMS) depends on disease activity.
Objective: To assess the real-world situation in monitoring disease activity in SPMS patients and to identify associations of resulting subgroups with demographics, symptomatology, and therapy METHODS: This study included 4,263 SPMS patients from the German MS register (GMSR). For the classification into 'active' and 'inactive' according to relapse activity and MRI findings during the year prior to the latest clinical visit, we used the following definitions: active - gadolinium enhancing (Gd+)/new T2 lesions or ≥1 relapse, inactive - neither Gd+/new T2 lesions nor relapses. The active, inactive, and unclassifiable patients were compared in terms of clinical data, socio-demographics, symptomatology, healthcare, and DMT.
Results: Classification was possible for 1,513 (35.5%) SPMS patients, with 467 classified as active and 1,046 as inactive. For the classification, MRI data was available for 33.2% of the 4,263 patients. Higher MRI frequencies were observed for younger patients (OR 1.22 [1.12,1.33] per 10 years) with short disease duration (OR 1.19 [1.09, 1.30] per 10 years) (p < 0.001).
Conclusion: MRI coverage was low, especially in elderly SPMS patients. Roughly one third of the SPMS patients presented markers of disease activity in the last year. Overall, the clinical differences (concerning symptomatology and care) between patients with active and inactive SPMS were small.
Keywords: Care; Classification; Disease activity; Disease course; Multiple sclerosis; Secondary progressive.
Copyright © 2021. Published by Elsevier B.V.
Similar articles
-
Difficulty in identification of patients with active secondary progressive multiple sclerosis by clinical classification tools.Eur J Neurol. 2022 Apr;29(4):1100-1105. doi: 10.1111/ene.15227. Epub 2022 Jan 5. Eur J Neurol. 2022. PMID: 34939266
-
Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.Mult Scler Relat Disord. 2021 May;50:102778. doi: 10.1016/j.msard.2021.102778. Epub 2021 Jan 28. Mult Scler Relat Disord. 2021. PMID: 33592384 Review.
-
Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis.Mult Scler Relat Disord. 2022 Dec;68:104220. doi: 10.1016/j.msard.2022.104220. Epub 2022 Oct 5. Mult Scler Relat Disord. 2022. PMID: 36242804
-
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors.Mult Scler. 2021 Mar;27(3):430-438. doi: 10.1177/1352458520974366. Epub 2020 Nov 19. Mult Scler. 2021. PMID: 33210986
-
Management of worsening multiple sclerosis with mitoxantrone: a review.Clin Ther. 2006 Apr;28(4):461-74. doi: 10.1016/j.clinthera.2006.04.013. Clin Ther. 2006. PMID: 16750460 Review.
Cited by
-
Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programme.Mult Scler J Exp Transl Clin. 2024 Jan 12;10(1):20552173231226106. doi: 10.1177/20552173231226106. eCollection 2024 Jan-Mar. Mult Scler J Exp Transl Clin. 2024. PMID: 38222025 Free PMC article.
-
Arginine vasopressin hormone receptor antagonists in experimental autoimmune encephalomyelitis rodent models: A new approach for human multiple sclerosis treatment.Front Neurosci. 2023 Mar 14;17:1138627. doi: 10.3389/fnins.2023.1138627. eCollection 2023. Front Neurosci. 2023. PMID: 36998727 Free PMC article. Review.
-
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis - a review of population-specific evidence from randomized clinical trials.Ther Adv Neurol Disord. 2023 Jan 24;16:17562864221146836. doi: 10.1177/17562864221146836. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 36710720 Free PMC article. Review.
-
Genetic risk variants for multiple sclerosis are linked to differences in alternative pre-mRNA splicing.Front Immunol. 2022 Oct 28;13:931831. doi: 10.3389/fimmu.2022.931831. eCollection 2022. Front Immunol. 2022. PMID: 36405756 Free PMC article.
-
Implication of genetic variants in primary microRNA processing sites in the risk of multiple sclerosis.EBioMedicine. 2022 Jun;80:104052. doi: 10.1016/j.ebiom.2022.104052. Epub 2022 May 10. EBioMedicine. 2022. PMID: 35561450 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
